Purpose: Immunecheckpointblockades(ICB)havebeensuccessfulingastriccancer (GC).However,themajorityofunselectedpatientswithGCfailtorespondtoICB.Itis crucialtoidentifyprecisebiomarkerstopredictresponsetoICB. Methods: Geneexpressionprofilingofformalin-fixedandparaffin-embeddedGCtissues from25patientstreatedwithICB(pembrolizumab)targetingprogrammedcelldeathpro-tein1(PD-1)wasperformedusingNanoString(NanoStringTechnologies).Fordevelop-mentofagenesignaturetopredictresponsetoICB,differentialgeneexpressionanalysis withlinearregressionmodelingwasperformedwithareaunderthecurvepackagesinR. Results: Fromtheanalysis,10genesweredifferentiallyexpressedbetweenpatientswith responseandnoresponsetoICB(P< 0.01).Toidentifyabiomarkerpredictingresponseto ICB,fourgeneswereselectedbasedon|log 2 (foldchange)|≥ 1.AftercalculatingtheIMmu-notherapyAgainstGastrIcCancer(IMAGiC)score,patientsweredividedintotwogroups:to beresponderandtobenon-responder,accordingtoResponseEvaluationCriteriainSolid Tumors(RECIST)guidelines.TheIMAGiCscorewassignificantlyassociatedwithRECIST groups(P = 0.0057),Epstein-Barrvirus(P = 0.048),andtumormutationalload(P = 0.023); however,wasnotsignificantlycorrelatedwithmicrosatelliteinstabilitystatus(P = 0.14) andprogrammeddeathligand1(PD-L1)expression(P= 0.095).ToreproduceIMAGiCwith differenttechnology,weretestedtheresultswithaquantitativereal-timepolymerase chainreaction(qRT-PCR)method,andtheprecisionofreproductionof87.5%.Invalida-tioncohortwith17samplesfromtheongoingtrialwithnivolumab,theprecisionofIMAG-iCqRT-PCRwas100%. Conclusion: OuridentifiedgenesignaturesandproposedIMAGiCmodelforpredicting responsetopembrolizumabinpatientswithGCshowedvalidity.
INTRODUCTION
Gastriccancer(GC)isthemostcommoncancerandthethird leadingcauseofcancerdeathworldwide [1] .TheU.S.Food andDrugAdministration(FDA)approvedpembrolizumab,an antibodyagainstprogrammedcelldeathprotein1(PD-1),to treatpatientswithadvancedsolidtumorsbearingthemicrosatelliteunstable(MSI)/DNAmismatchrepair(dMMR)-deficientbiomarker [2] .Arecentnonrandomized,multicenter, multicohortbaskettrialofpembrolizumabin475patients withoneof20differentprogrammeddeathligand1(PD-L1) -positiveadvancedsolidtumorsshoweddiverseobjectiveresponserates(ORRs)acrossdifferentcancertypes.Biomarkers thatcanpredictresponsetoanti-PD-1therapyacrossmulti-pletumortypesincludeT-cellinflamedgeneexpressionprofile(GEP),PD-L1expression,and/ortumormutationalburden (TMB) [3] .However,largerstudiesareneededtoobtainmore precisionwithinindividualcancertypesandtoassessthepotentialclinicalutilityofdevelopingcutoffsforsuchbiomarkersinpatientselectionforanti-PD-1therapy [3] .
InGC,asingle-arm,multicohort,pembrolizumabphase2 trial(KEYNOTE-059)showedanORRof11.6%,and2.3%ofthe patientsshowedcompleteresponses(CRs),withalowerpro-portionofrespondersamongpatientswithGCcomparedto patientswithnon-smallcelllungcancer [4] .Thehighproportionofnon-respondersandtheemergenceofresistanceinpatientswhodoinitiallyrespondposesignificantchallengesin thefieldofcancerimmunotherapy [5] .Arecentmolecular Reproduction of test with quantitative real-time polymerase chain reaction 
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Differentially expressed genes in responses to pembrolizumab
Analyses of IMAGiC in TCGA and ACRG cohorts
AsPD-1blockadeshavebeenshowntobeeffectiveforMSI [6, 14] andEBV-positivetumors [15] [16] [17] aswellfortumors withhighTMB [18, 19] ,weappliedtheIMAGiCprediction modelforTCGARNAsequencingdata(n = 260) [10] andACRG mRNAexpressionarrayresults(n = 300) [20] .
IntheTCGAgroup,therewere59cases(22.7%)withMSI,24 MSIandTMBweresignificantlyhigherthanthoseinthemicrosatellitestable(MSS)andno-TMBgroups (Fig.3B,C) .
InACRG,68(22.7%)wereMSIand18(6.0%)wereEBV-positivesubtypes(Table3).WefoundthatIMAGiCgroupswere associatedwithrecurrence-freesurvival,ACRGmolecular subtype(P = 1.96E-08),andMSI(P = 0.006)( Fig.4 ). 
Reproduction and validation of IMAGiC with qRT-PCR
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